Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
META-1: Anti-PD1 Monotherapy in 1L Advanced NSCLC Patients With PD-L1 TPS > 50% and PTI=0
NCT07360743Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Unicancer. Primary endpoint: Rate of patients without early progression at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
pembrolizumabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07360743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360743.